Results 161 to 170 of about 13,013 (192)

Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset. [PDF]

open access: yesOncogene
Wang J   +23 more
europepmc   +1 more source

Disruption of KMT2D Perturbs Germinal Center B Cell Development and Promotes Lymphomagenesis

open access: yesNature Medicine, 2015
Mutations in the gene encoding the KMT2D (or MLL2) methyltransferase are highly recurrent and occur early during tumorigenesis in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL).
Laura Pasqualucci   +2 more
exaly   +2 more sources
Some of the next articles are maybe not open access.

Related searches:

Small Molecule Inhibitors of the Prostate Cancer Target KMT2D

Biochemical and Biophysical Research Communications, 2020
Histone lysine N-methyltransferase 2D (KMT2D), an important methyltransferase that is involved in the methylation of lysine 4 in histone H3 (H3K4) and related to the development of prostate cancer. Hypermethylation of H3K4 is shown in prostate cancer (PCa). However, KMT2D inhibitors have not yet been developed.
Guochao Liao, Zhongqiu Liu, Qi Yu
exaly   +3 more sources

KMT2C And KMT2D Aberrations in Breast Cancer

open access: yesTrends in Cancer
KMT2C and KMT2D are histone lysine methyltransferases responsible for the monomethylation of histone 3 lysine 4 (H3K4) residues at gene enhancer sites. KMT2C/D are the most frequently mutated histone methyltransferases (HMTs) in breast cancer, occurring at frequencies of 10-20% collectively. Frequent damaging and truncating somatic mutations indicate a
Sinead Toomey, Simon J. Furney
exaly   +5 more sources

Near complete deletion of KMT2D in a college student

American Journal of Medical Genetics Part A, 2022
AbstractPathogenic variants in KMT2D are typically associated with Kabuki syndrome (KS), a rare multisystem disorder. KS is characterized by facial dysmorphisms, intellectual disability, skeletal and dermatoglyphic differences, and poor growth. Seventy percent of individuals with clinically diagnosed KS have a confirmed pathogenic variant in KMT2D or ...
Catherine Gooch   +8 more
openaire   +2 more sources

Methylation of the Chromatin Modifier KMT2D by SMYD2 Contributes to Therapeutic Response in Hormone-Dependent Breast Cancer [PDF]

open access: yesCell Reports
Activating mutations in PIK3CA are frequently found in estrogen-receptor-positive (ER+) breast cancer, and the combination of the phosphatidylinositol 3-kinase (PI3K) inhibitor alpelisib with anti-ER inhibitors is approved for therapy. We have previously
Hongkai Ji, Eneda Toska, Peihua Zhao
exaly   +2 more sources

Characteristics of epilepsy in patients with Kabuki syndrome with KMT2D mutations

Brain and Development, 2017
The characteristics of epilepsy in patients with Kabuki syndrome with KMT2D mutations (KABUK1) have not yet been well documented. This is the first review to explore this.We enrolled 14 patients with KABUK1, whose median age was 13.6years (range=4.1-21.3years).
Naoko, Kurahashi   +13 more
openaire   +2 more sources

Neuroimaging in Kabuki syndrome and another KMT2D‐related disorder

American Journal of Medical Genetics Part A, 2021
AbstractRecognition of distinct phenotypic features is an important component of genetic diagnosis. Although CHARGE syndrome, Kabuki syndrome, and a recently delineated KMT2D Ex 38/39 allelic disorder exhibit significant overlap, differences on neuroimaging may help distinguish these conditions and guide genetic testing and variant interpretation.
Rachel T. Stadelmaier   +7 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy